<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01354886</url>
  </required_header>
  <id_info>
    <org_study_id>GEXGP240101</org_study_id>
    <nct_id>NCT01354886</nct_id>
  </id_info>
  <brief_title>Single Dose FSH-GEX™ in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Monocenter, Randomized, Placebo and Comparator Controlled, Single Blind, Rising Dose, Clinical Study to Determine Single Dose Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Four Doses of FSH-GEX™ According to Adaptive Design (25, 75, 150 and 300 IU) Administered Subcutaneously in Healthy Pituitary-suppressed Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glycotope GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glycotope Biotechnology GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Glycotope GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study was the pharmacokinetic and pharmacodynamic characterization of&#xD;
      a single dose administration of four doses of FSH-GEX™ in healthy pituitary-suppressed female&#xD;
      volunteers, in comparison with two marketed comparator products.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy pituitary-suppressed female subjects received FSH-GEX™ (25, 75, 150 and 300 IU) in&#xD;
      three of four possible ascending doses or one dose of two comparators (Bravelle® and&#xD;
      Gonal-f®) and placebo in random order. The study consisted of three separate treatment&#xD;
      periods. During each treatment period the subject received one single dose via a subcutaneous&#xD;
      injection in the lower abdominal wall.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to assess the safety and (local) tolerability of FSH-GEX™ following single rising dose administration by subcutaneous injection</measure>
    <time_frame>up to 87 days</time_frame>
    <description>frequency of dose related adverse events, measurement of vital signs, body measurements, transvaginal ultrasound, ECG and laboratory values in comparison to placebo and the two comparators with marketing authorization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>to determine FSH pharmacokinetic parameters of FSH-GEX™ following single dose administration by subcutaneous injection (part 1)</measure>
    <time_frame>before FSH/Placebo administration until 240 hours thereafter</time_frame>
    <description>Peak plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>to determine FSH pharmacokinetic parameters of FSH-GEX™ following single dose administration by subcutaneous injection (part 2)</measure>
    <time_frame>before FSH/Placebo administration until 240 hours thereafter</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>to assess the pharmacodynamic effect of FSH-GEX™ following single rising dose administration by subcutaneous injection (part 1)</measure>
    <time_frame>before FSH/Placebo administration until 240 hours thereafter</time_frame>
    <description>determined by Estradiol (E2) and inhibin B concentrations depending on dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to assess the pharmacodynamic effect of FSH-GEX™ following single rising dose administration by subcutaneous injection (part 2)</measure>
    <time_frame>up to a maximum of 87 days</time_frame>
    <description>ovarian follicle number and size as determined by transvaginal ultrasonography depending on dose</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Female Infertility</condition>
  <arm_group>
    <arm_group_label>FSH-GEX 25 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 IU single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FSH-GEX 75 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 IU single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FSH-GEX 150 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 IU single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FSH-GEX 300 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 IU single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gonal-f</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 IU single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bravelle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 IU single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FSH-GEX™</intervention_name>
    <description>single dose</description>
    <arm_group_label>FSH-GEX 150 IU</arm_group_label>
    <arm_group_label>FSH-GEX 25 IU</arm_group_label>
    <arm_group_label>FSH-GEX 300 IU</arm_group_label>
    <arm_group_label>FSH-GEX 75 IU</arm_group_label>
    <other_name>follitropin epsilon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonal-f</intervention_name>
    <description>150 IU single dose</description>
    <arm_group_label>Gonal-f</arm_group_label>
    <other_name>follitropin alfa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bravelle</intervention_name>
    <description>150 IU single dose</description>
    <arm_group_label>Bravelle</arm_group_label>
    <other_name>urinary FSH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female subjects from 18-40 years of age.&#xD;
&#xD;
          2. Subjects must be in good health.&#xD;
&#xD;
          3. Subjects must be willing to use additional non-hormonal contraception&#xD;
&#xD;
          4. Subjects must have used a combined oral contraceptive (COC) for at least one cycle.&#xD;
&#xD;
          5. Vital signs which are within the following ranges at baseline measurements: systolic&#xD;
             blood pressure of 90-140 mmHg, diastolic blood pressure of 50-90 mmHg and pulse rate&#xD;
             of 40 - 100 bpm.&#xD;
&#xD;
          6. Subjects must have a body weight of minimally 50.0 kg with a BMI between 18.0 and 29.0&#xD;
             kg/m^2 at baseline measurements.&#xD;
&#xD;
          7. Able to provide written informed consent prior to study participation.&#xD;
&#xD;
          8. Able to communicate well with the investigator and to understand and comply with the&#xD;
             requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Smokers of more than 10 cigarettes per day.&#xD;
&#xD;
          2. Average daily intake of more than 3 units of alcohol per day or an average weekly&#xD;
             intake of more than 21 units alcohol.&#xD;
&#xD;
          3. Use of any prescription drug or ove the counter medication from screening until the&#xD;
             end-of-study visit, without prior approval of the investigator.&#xD;
&#xD;
          4. Any drugs thay may reduce the effectiveness of COC from screening until the&#xD;
             end-of-study visit.&#xD;
&#xD;
          5. Any follicle-stimulating hormone (FSH) preparation within 90 days prior to screening.&#xD;
&#xD;
          6. Administration of any investigational product or use of any investigational device&#xD;
             within 30 days prior to screening.&#xD;
&#xD;
          7. Donation or loss of 500 mL or more blood within 90 days prior to first FSH-GEX™&#xD;
             dosing.&#xD;
&#xD;
          8. History of acute or chronic bronchospastic disease (including asthma and chronic&#xD;
             obstructive pulmonary disease, treated or not treated).&#xD;
&#xD;
          9. History of allergies for drugs, seafood, nuts, eggs, wasp-stings; history of atopic&#xD;
             allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to any of&#xD;
             the study drugs.&#xD;
&#xD;
         10. Any surgical or medical condition which might alter the absorption, distribution,&#xD;
             metabolism, or excretion of drugs or which may jeopardize the subject in case of&#xD;
             participation in the study.&#xD;
&#xD;
         11. History or presence of any malignancy.&#xD;
&#xD;
         12. Determined or suspected pregnancy.&#xD;
&#xD;
         13. Breast feeding women.&#xD;
&#xD;
         14. History of (or current) endocrine abnormalities.&#xD;
&#xD;
         15. Contraindication for the use of oral contraceptives.&#xD;
&#xD;
         16. Contraindication for the use of follitropin alfa, FSH or any of the excipients&#xD;
             (hypersensitivity to follitropin alfa, FSH or any of the excipients; tumors of the&#xD;
             hypothalamus or the pituitary gland; ovarian enlargement or cyst not due to polycystic&#xD;
             ovarian disease; gynecological bleeding of unknown origin; ovarian, uterine, or&#xD;
             mammary carcinoma).&#xD;
&#xD;
         17. Porphyria or family history of porphyria.&#xD;
&#xD;
         18. History of ovarian surgery.&#xD;
&#xD;
         19. Any ovarian or abdominal abnormality that would interfere with adequate ultrasound&#xD;
             investigation.&#xD;
&#xD;
         20. An abnormal cervical smear.&#xD;
&#xD;
         21. History or presence of an immune-compromising disease, or a positive human&#xD;
             immunodeficiency virus (HIV) test result in the past or at the screening visit.&#xD;
&#xD;
         22. History of Hepatitis B or C, or a positive Hepatitis B surface antigen (HBsAg) or&#xD;
             Hepatitis C test result at the screening visit.&#xD;
&#xD;
         23. History of drug or alcohol abuse within the 12 months prior to the screening visit or&#xD;
             evidence of such abuse.&#xD;
&#xD;
         24. Planned surgery or hospitalization during the period of the study.&#xD;
&#xD;
         25. Concurrent participation or participation within 30 days before screening in another&#xD;
             clinical trial, or participation in more than 3 clinical studies within 12 months,&#xD;
             prior to the expected date of enrolment into the study.&#xD;
&#xD;
         26. Injection of one or more doses of any depot contraceptive drug /drug combination or&#xD;
             hormonal implants &lt;= 10 months prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glycotope GmbH</last_name>
    <role>Study Director</role>
    <affiliation>Glycotope GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glycotope Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Abd-Elaziz K, Duijkers I, Stöckl L, Dietrich B, Klipping C, Eckert K, Goletz S. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials. Hum Reprod. 2017 Aug 1;32(8):1639-1647. doi: 10.1093/humrep/dex220.</citation>
    <PMID>28591833</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 11, 2011</study_first_submitted>
  <study_first_submitted_qc>May 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2011</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>in-vitro fertilization</keyword>
  <keyword>reproductive disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

